zamperini on ADC Therapeutics SA (ADCT)

Pitch Summary ADC Therapeutics is a commercial-stage oncology biotech with one approved product, ZYNLONTA (loncastuximab tesirine), currently generating roughly ~$70M annual revenue in 3L+ DLBCL. The stock is priced like a melting-ice-cube microcap despite a durable cash-generating base asset and two legitimate “make-or-break” expansion shots on goal in 2L+ DLBCL (LOTIS-5 with rituximab; LOTIS-7 with Columvi/glofitamab). The bull case is straightforward: success in LOTIS-5 expands addressable use cases and moves ZYNLONTA from niche salvage therapy toward a broader 2L backbone option, while LOTIS-7 could create a best-in-class combo regimen that drives meaningfully higher peak sales. The market’s skepticism is anchored in past pipeline disappointments, dilution, and intensifying DLBCL competition from CAR-T and bispecifics, so ADCT gets no credit for upside until data prints. Management has narrowed focus and is cutting the burn rate, which matters because this is a “data-to-cash-flow” bridge story rather than a platform-premium story. If ZYNLONTA expands and opex resets, the equity can re-rate multiple turns on a credible path to several hundred million in revenue over the next 5–6 years. Key risks are obvious: trial failure, safety/tolerability surprises in combos, slower physician adoption, and ongoing dilution if timelines slip.

BSD Analysis ADCT is a perpetual capital destroyer with a single-asset cliff, when in reality it is a levered call on clinical de-risking with an FDA-approved drug already anchoring the enterprise. Business quality is understated: ZYNLONTA provides real-world presence, physician familiarity, and a commercial infrastructure that meaningfully lowers the hurdle for combination adoption. What the market is missing is the strategic “combo logic” in DLBCL—rapid cytoreduction plus durability—which positions ADCT as a potential backbone rather than a marginal line-extension if LOTIS-5/7 data are positive. Valuation looks superficially cheap because confidence is broken, not because the opportunity is small; any credible efficacy signal can drive a sharp re-rating given how little success is priced in. Governance and capital allocation matter acutely here—cash runway discipline and avoiding pre-data dilution are critical to preserving upside asymmetry. Position sizing should be explicitly event-driven and limited, reflecting binary outcomes rather than compounding fundamentals. The thesis breaks on equivocal or negative LOTIS-5 results, unexpected safety signals in combinations, or a funding need that forces punitive dilution ahead of key readouts.

Original Source https://www.valueinvestorsclub.com/idea/ADC_THERAPEUTICS_SA/6708395333